Geron Corp - GERN STOCK NEWS

Geron Corporation (NASDAQ: GERN) announced promising data from its IMerge Phase 2 study on Imetelstat, a telomerase inhibitor, showing over 29% of lower risk MDS patients achieved greater than one-year transfusion independence. The upcoming ASH Annual Meeting will feature multiple abstracts highlighting its efficacy in hematologic malignancies, with Phase 3 IMerge trial top-line results expected in early January 2023. Imetelstat's safety profile is consistent, with reversible adverse effects. The research indicates potential disease-modifying activity, addressing significant needs in blood cancer treatments.

Geron Corporation (Nasdaq: GERN) reported its Q3 2022 financial results, revealing a net loss of $41.1 million ($0.10 per share), up from $26.7 million ($0.08 per share) in Q3 2021. Revenues were $297,000, a significant increase from $109,000 in the same period last year. The company has approximately $195 million in cash, with additional resources expected to fund operations through mid-2024. Top-line results from the IMerge Phase 3 trial on imetelstat are anticipated in January 2023, with a New Drug Application submission planned for 2023. Geron projects total operating expenses for 2022 between $155 million and $165 million.

Geron Corporation (NASDAQ: GERN) will announce its Q3 2022 financial results before the market opens on November 3, 2022. A conference call will be held at 9:00 a.m. ET the same day to discuss these results and key milestones. Participants can access the call via a live webcast or by phone. Geron is focused on developing imetelstat, a first-in-class telomerase inhibitor, currently undergoing two Phase 3 clinical trials for hematologic malignancies.

On October 19, 2022, Geron Corporation (NASDAQ: GERN) granted non-statutory stock options for 843,260 shares of common stock to newly hired employees. The options have an exercise price of $2.25, matching the closing price on the grant date. Of these, 710,000 shares will vest over four years, while 133,260 shares will vest upon achieving regulatory milestones. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and supports Geron's commitment to developing its telomerase inhibitor, imetelstat, currently in two Phase 3 trials for hematologic malignancies.

Geron Corporation (NASDAQ: GERN) announced the granting of stock options to purchase 901,950 shares of common stock to newly hired employees as an inducement for employment. The options were issued on September 21, 2022, at an exercise price of $2.54 per share, equal to the stock's closing price on that day. Of the total, 495,800 shares vest over four years while 406,150 shares vest upon achieving specific regulatory milestones. This grant aligns with Nasdaq rules and Geron's 2018 Inducement Award Plan.

Geron Corporation (NASDAQ: GERN) appointed John F. McDonald to its Board of Directors effective September 7, 2022. McDonald, a seasoned executive with over 30 years in the biopharmaceutical industry, aims to enhance Geron's strategic and commercial objectives, particularly in advancing imetelstat. His past roles include leadership positions at Novo Nordisk and Biogen. The company's clinical focus remains on the telomerase inhibitor, imetelstat, currently undergoing two Phase 3 trials for hematologic malignancies, with top-line results expected in early January 2023.

Geron Corporation (Nasdaq: GERN) has announced that CEO John A. Scarlett will present at three major investor conferences in New York City. The events include the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, and the Baird 2022 Global Healthcare Conference on September 14, 2022. Webcasts will be available on Geron's website and archived for 30 days. Geron focuses on developing its first-in-class telomerase inhibitor, imetelstat, for treating hematologic malignancies.

Geron Corporation (NASDAQ: GERN) has initiated the IMproveMF Phase 1 study, aimed at evaluating the combination of imetelstat and ruxolitinib in frontline myelofibrosis patients. Preclinical data indicated promising effects of this combination. The study will assess safety, pharmacokinetics, and clinical activity, with the first patient already dosed. Results are anticipated by late 2023. Imetelstat, a first-in-class telomerase inhibitor, shows potential in modifying disease progression in myelofibrosis, setting it apart from existing treatments.

Geron Corporation (NASDAQ: GERN) announced the granting of non-statutory stock options for 365,800 shares to new employees as part of their employment inducement. The options were granted on August 17, 2022, at an exercise price of $2.15 per share, equivalent to the closing stock price on that date. These options have a 10-year term and vest over four years, rewarding continued employment. This grant follows Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan.